DE60140200D1 - Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung - Google Patents

Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Info

Publication number
DE60140200D1
DE60140200D1 DE60140200T DE60140200T DE60140200D1 DE 60140200 D1 DE60140200 D1 DE 60140200D1 DE 60140200 T DE60140200 T DE 60140200T DE 60140200 T DE60140200 T DE 60140200T DE 60140200 D1 DE60140200 D1 DE 60140200D1
Authority
DE
Germany
Prior art keywords
compositions
methods
administration
vivo method
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140200T
Other languages
English (en)
Inventor
Kevin J Donahue
Eduardo Marban
Koichi Nagata
John H Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60140200D1 publication Critical patent/DE60140200D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
DE60140200T 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung Expired - Lifetime DE60140200D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24023100P 2000-10-13 2000-10-13
PCT/US2001/032274 WO2002030470A1 (en) 2000-10-13 2001-10-15 Methods and compositions for nucleic acid delivery

Publications (1)

Publication Number Publication Date
DE60140200D1 true DE60140200D1 (de) 2009-11-26

Family

ID=22905689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140200T Expired - Lifetime DE60140200D1 (de) 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Country Status (8)

Country Link
US (1) US6992070B2 (de)
EP (1) EP1331950B1 (de)
JP (1) JP2004534719A (de)
AT (1) ATE445417T1 (de)
AU (1) AU2002214596A1 (de)
CA (1) CA2425835A1 (de)
DE (1) DE60140200D1 (de)
WO (1) WO2002030470A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8880701A (en) * 2000-09-06 2002-03-22 Univ Johns Hopkins Cardiac arrhythmia treatment methods
US20090175790A1 (en) * 2000-09-06 2009-07-09 The Johns Hopkins University Cardiac arrhythmia treatment methods and biological pacemaker
US6992070B2 (en) 2000-10-13 2006-01-31 The Johns Hopkins University Methods and compositions for nucleic acid delivery
IL158618A0 (en) * 2001-04-27 2004-05-12 Univ Johns Hopkins Biological pacemaker
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US8003618B2 (en) * 2002-10-02 2011-08-23 The John Hopkins University Focal calcium channel modulation
BR0314931A (pt) * 2002-10-09 2005-08-02 Pfizer Prod Inc Composições estabilizadas de dna isolado
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US7722596B2 (en) * 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US20070203445A1 (en) * 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
US8759317B2 (en) 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
WO2006074443A2 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2006089340A2 (en) * 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US20090304588A1 (en) * 2005-10-14 2009-12-10 The Johns Hopkins University Biologically excitable cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US20090047703A1 (en) * 2007-08-17 2009-02-19 University Of Maryland, Baltimore ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease
AU2008350903B2 (en) 2008-02-19 2015-04-02 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20100041984A1 (en) * 2008-08-12 2010-02-18 James Edward Shapland Impedance sensing device and catheter system
US9050400B2 (en) * 2008-08-12 2015-06-09 Osprey Medical, Inc. Remote sensing catheter system and methods
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2741804B1 (de) 2011-08-11 2017-04-26 Osprey Medical Inc. Systeme und verfahren zur behandlung der gliedmassen
CN103920161A (zh) * 2014-03-27 2014-07-16 浙江大学 一种在细胞膜微囊中高效装载药物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516651A (en) * 1991-11-15 1996-05-14 The General Hospital Corporation Nucleic acids encoding calcitonin receptor and uses thereof
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6237077B1 (en) 1997-10-13 2001-05-22 Idea Corporation Instruction template for efficient processing clustered branch instructions
EP1041882A4 (de) 1997-12-19 2002-04-17 Univ Pennsylvania Transvaskuläre verabreichung einer zusammensetzung an ein extravaskuläres gewebe eines säugetieres
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
US6992070B2 (en) 2000-10-13 2006-01-31 The Johns Hopkins University Methods and compositions for nucleic acid delivery

Also Published As

Publication number Publication date
CA2425835A1 (en) 2002-04-18
EP1331950A1 (de) 2003-08-06
US20020094326A1 (en) 2002-07-18
EP1331950B1 (de) 2009-10-14
JP2004534719A (ja) 2004-11-18
WO2002030470A9 (en) 2003-02-06
AU2002214596A1 (en) 2002-04-22
WO2002030470A1 (en) 2002-04-18
US6992070B2 (en) 2006-01-31
ATE445417T1 (de) 2009-10-15
WO2002030470A8 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
WO2020198509A3 (en) Modified oligonucleotides with increased stability
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
DE60238416D1 (de) Plasmaprotein-matritzes und verfahren zu ihrer herstellung
AR040396A1 (es) Citoquinas protectoras de tejidos para la proteccion, restauracion y mejoramiento de celulas, tejidos y organos receptivos
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
JP2008005844A (ja) 特定遺伝子の発現を抑制するための方法および薬剤
WO1998049300A3 (en) Truncated vegf-related proteins
ATE277645T1 (de) Peptid-beschichtete implantate und verfahren zu ihrer herstellung
DE602005025347D1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
NO20055209D0 (no) Peptabody for cancerbehandling
ES2530872T3 (es) Organos y células modificados para xenotrasplante
ATE495254T1 (de) Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
US11857598B2 (en) Self-replicating cell selective gene delivery compositions, methods, and uses thereof
ATE385252T1 (de) Verfahren zur herstellung von granulatförmigen zusammensetzungen
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
WO2006128885A3 (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
DE60114193D1 (de) Transfektionssystem
ATE312173T1 (de) Methoden und zusammensetzungen zur aufklärung von proteinexpressionsprofilen in zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US

R082 Change of representative

Ref document number: 1331950

Country of ref document: EP

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, 80539